SCHEMBL3324154

SCHEMBL3324154

CCOCCOC(=O)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(O)c(OC)c1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 15/20 0.75
GAA P10253 11/20 0.75
RAD52 P43351 1/20 0.69
ALDH1A1 P00352 11/20 0.64
HPGD P15428 6/20 0.64
HSD17B10 Q99714 5/20 0.64
CASP1 P29466 5/20 0.61
CASP7 P55210 4/20 0.61
USP2 O75604 2/20 0.61
PKM P14618 1/20 0.61
TSHR P16473 2/20 0.61
ALOX15 P16050 2/20 0.59
RECQL P46063 1/20 0.59
HTT P42858 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
GLA P06280 2/20 0.57
MCL1 Q07820 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324039 0.88 KDM4E (0.68) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL12135872 0.86 KDM4E (0.74) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL3325478 0.84 KDM4E (0.69) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL3321253 0.81 KDM4E (0.80) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL18415245 0.81 RAD52 (1.00) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL3325407 0.81 KDM4E (0.68) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL3325190 0.81 KDM4E (0.68) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL3326494 0.81 KDM4E (0.65) KDM4EGAARAD52ALDH1A1HPGD
SCHEMBL3323765 0.81 KDM4E (0.73) KDM4EGAAALDH1A1HPGDHSD17B10
SCHEMBL5333914 0.79 ALDH1A1 (0.66) KDM4EGAAALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 KDM4E 4115/4885GAA 271/4885RAD52 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.